Meridiem Capital Partners LP Sells 49,567 Shares of Charles River Laboratories International, Inc. $CRL

Meridiem Capital Partners LP cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 41.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 70,467 shares of the medical research company’s stock after selling 49,567 shares during the period. Meridiem Capital Partners LP owned 0.14% of Charles River Laboratories International worth $11,025,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Jones Financial Companies Lllp raised its holdings in Charles River Laboratories International by 167.6% in the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after purchasing an additional 1,074 shares during the period. Empowered Funds LLC bought a new stake in Charles River Laboratories International during the first quarter valued at about $418,000. Fox Run Management L.L.C. purchased a new stake in Charles River Laboratories International in the second quarter worth about $400,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Charles River Laboratories International by 2.7% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 55,943 shares of the medical research company’s stock worth $8,488,000 after buying an additional 1,486 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of Charles River Laboratories International in the second quarter worth about $803,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Price Performance

NYSE CRL traded up $2.60 during trading hours on Friday, reaching $155.26. The company’s stock had a trading volume of 115,798 shares, compared to its average volume of 996,369. The firm’s 50-day moving average price is $192.53 and its 200-day moving average price is $180.94. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $228.88. The company has a market capitalization of $7.64 billion, a price-to-earnings ratio of -52.50, a PEG ratio of 2.89 and a beta of 1.64.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.33 by $0.06. The business had revenue of $994.23 million during the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The company’s revenue was down .8% on a year-over-year basis. During the same period last year, the firm posted $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on CRL. Argus set a $200.00 price objective on Charles River Laboratories International in a research note on Monday, November 17th. Mizuho lowered their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a report on Friday, February 20th. Wall Street Zen lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Evercore increased their price objective on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Finally, Morgan Stanley set a $185.00 target price on shares of Charles River Laboratories International in a research note on Monday, December 1st. Ten equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $203.57.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Zacks raised several medium‑ and long‑term EPS forecasts, lifting FY2026 to $10.78 (from $10.68), FY2027 to $11.62 (from $11.30) and publishing a FY2028 view of $12.12 — indicating expectations for improving profitability beyond the near term. Zacks raises FY2026–FY2028 estimates
• Positive Sentiment: Zacks also bumped several quarterly estimates (examples: Q2 2026 to $2.85, Q3 2026 to $2.86, Q3 2027 to $3.02, Q4 2026 to $3.02 and Q4 2027 to $3.32), reinforcing a view of recurring quarter‑to‑quarter improvement. Zacks raises multiple quarterly estimates
• Neutral Sentiment: A few estimate moves were small/immaterial (e.g., Q2 2027 trimmed slightly to $2.65 from $2.67), which are unlikely to move fundamentals materially but show analysts fine‑tuning models. Minor estimate adjustments
• Negative Sentiment: Zacks cut Q1 2026 EPS significantly to $2.05 from $2.39 — a notable near‑term downgrade that likely triggered the negative intraday reaction as it reduces near‑term earnings visibility despite better longer‑term estimates. Q1 2026 estimate cut

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.